$32.44
+
$0.13 (0.40%)
End-of-day quote: 03/11/2024
NasdaqGS:CBAY
CymaBay Therapeutics Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$31.07M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $10.00M | $0.00M | $0.00M | $0.00M | |
| GM % | Gross Margin % |
|
-160.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -20.04% | 0.00% | 0.00% | 0.00% | |
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -213.25% | 0.00% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $-0.99 | $-1.21 | $-1.27 | $-0.75 | $-1.46 | $-1.25 | $-0.79 | $-1.14 | $-0.82 | $-2.65 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
-0.00% | 0 | 0 | 0 | -0.00% | -0.00% | 0 | 0 | 0 | 0 | |
| Sha. | Shares |
|
113.86m | 84.68m | 84.68m | 68.95m | 68.88m | 59.46m | 44.41m | 23.45m | 23.45m | 14.7m | |
| OCF | Operating Cash Flow |
|
$-72.53M | $-84.08M | $-69.43M | $-44.73M | $-97.91M | $-54.94M | $-19.63M | $-23.35M | $-23.32M | $-21.11M | |
| FCF | Free Cash Flow |
|
$-89.00M | $-84.23M | $-69.52M | $-44.75M | $-98.23M | $-55.47M | $-19.66M | $-23.39M | $0.00M | $-21.22M | |
| FCFS | Free Cash Flow Per Share |
|
$-0.69 | $-0.96 | $-0.98 | $-0.65 | $-1.47 | $-0.96 | $-0.56 | $-1.00 | $-1.23 | $-1.76 |
